Full Study Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled (Humira), Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Investigational drug in Participants With Moderately to Severely Active Crohn's Disease [INTREPID]

The primary objectives of this study is to evaluate the efficacy and safety of the investigational drug versus placebo (Stage 1) and versus Humira® (Stage 2) to achieve endoscopic response and clinical remission in participants with moderately to severely active Crohn's Disease (CD) who have failed or are intolerant to conventional therapy (corticosteroids or immunomodulators), or who are biological-treatment naive, have demonstrated a successful response to prior biological treatment, or who have failed or were intolerant to biological treatment.

Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]

The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.

To investigate the underlying mechanisms of sex differences in statural growth impairment and to develop a predictive model to identify patients at highest risk for developing growth impairment refractory to standard therapeutic approaches

The purpose of this research study is to compare the effects of the study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. PF-06651600 and PF-06700841 are investigational drugs.

The primary objectives of this study are to determine if an investigational drug called PF-06687234, is safe, tolerable, and effective as an add-on therapy to Infliximab in the treatment of patients with active ulcerative colitis.

The purpose of this research study is to help us understand whether a diet can help children with Ulcerative Colitis (UC) to feel better without needing to take additional medications. Currently, it is thought that UC causes an imbalance in the good and bad bacteria that live inside our gut. We also know that certain foods can change how these good and bad bacteria live, and possibly contribute to UC symptoms. We think a specific diet could help create a better balance in your gut and help you feel better. This study is trying to figure out if a diet can help treat UC.

Full Study Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy. (3027)

The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) maintenance treatment in participants with moderately to severely active ulcerative colitis (UC) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.

The main objective of this study is to evaluate the health of the bowel at Week 26 after taking vedolizumab using ileocolonoscopy.

Full Study Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy (Study 3031)

The Primary Objective is to assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in patients with moderately to severely active CD who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.

Full Study Title: An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease.

This study is designed to find out if having the medical conditions Ulcerative Colitis or Crohn’s Disease affects the way commonly used medications are broken down in the body.